BMS207147 is a orally-available, triazole-based antifungal with MICs 2- to 4-fold more potent than itraconazole and 40-fold more active than fluconazole against yeasts. In all but 9 of 116 Candida strains tested, BMS207147 had MICs of < 0.5 ug/mL. [1]  In oral mouse studies, BMS207147 was shown to have a 3-fold longer half-life than itraconazole. [2] 

In 541 clinical isolates of Cryptococcus neoformans, BMS207147 again proved to be more potent than itraconazole and fluconazole (0.25 ug/mL vs 0.5 ug/mL and 8 ug/mL). [3]